Production (Stage)
Bone Biologics Corporation
BBLG
$4.98
$0.040.81%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 36.52% | -13.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -33.21% | 63.50% | |||
| Operating Income | 33.21% | -63.50% | |||
| Income Before Tax | 33.16% | -61.71% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 33.16% | -61.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 33.16% | -61.71% | |||
| EBIT | 33.21% | -63.50% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 47.93% | 74.10% | |||
| Normalized Basic EPS | 47.93% | -14.34% | |||
| EPS Diluted | 47.93% | 74.10% | |||
| Normalized Diluted EPS | 47.93% | -14.34% | |||
| Average Basic Shares Outstanding | 28.35% | 41.45% | |||
| Average Diluted Shares Outstanding | 28.35% | 41.45% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||